The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Volume -, Issue -, Pages -
Publisher
The Endocrine Society
Online
2021-08-18
DOI
10.1210/clinem/dgab578
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)
- (2021) Juan P. Frias et al. DIABETES CARE
- GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis
- (2021) Thomas Karagiannis et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Exome-Wide Association Study on Alanine Aminotransferase Identifies Sequence Variants in the GPAM and APOE Associated With Fatty Liver Disease
- (2021) Oveis Jamialahmadi et al. GASTROENTEROLOGY
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity
- (2021) Thomas A. Wadden et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
- (2021) Melanie Davies et al. LANCET
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
- (2021) John P.H. Wilding et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity
- (2021) Domenica Rubino et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort
- (2021) Stephen A. Harrison et al. JOURNAL OF HEPATOLOGY
- Preparing for the NASH Epidemic: A Call to Action
- (2021) Fasiha Kanwal et al. GASTROENTEROLOGY
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
- (2021) Julio Rosenstock et al. LANCET
- Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
- (2021) Bernhard Ludvik et al. LANCET
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
- (2021) Juan P. Frías et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nonalcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know?
- (2020) Jeffrey Budd et al. AMERICAN JOURNAL OF MEDICINE
- NAFLD 2020: The State of the Disease
- (2020) Thomas G. Cotter et al. GASTROENTEROLOGY
- NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications
- (2020) Giovanni Targher et al. GUT
- Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5
- (2020) Robert F. Kushner et al. Obesity
- Screening for Liver Fibrosis and Steatosis in a Large Cohort of Patients with Type 2 Diabetes Using Vibration Controlled Transient Elastography and Controlled Attenuation Parameter in a Single-Center Real-Life Experience
- (2020) Ioan Sporea et al. Journal of Clinical Medicine
- Screening for Non-Alcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the U.S. is Cost Effective: A Comprehensive Cost-Utility Analysis
- (2020) Mazen Noureddin et al. GASTROENTEROLOGY
- Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)
- (2020) Mohammad S. Kuchay et al. DIABETOLOGIA
- Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors
- (2020) Alexandros Sachinidis et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Cardiovascular risk in patients with nonalcoholic fatty liver disease: looking at the liver to shield the heart
- (2020) Kenneth Cusi et al. CURRENT OPINION IN LIPIDOLOGY
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
- (2020) DIABETES CARE
- High Prevalence of Advanced Liver Fibrosis Assessed by Transient Elastography Among U.S. Adults With Type 2 Diabetes
- (2020) Stefano Ciardullo et al. DIABETES CARE
- Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening
- (2020) Romina Lomonaco et al. DIABETES CARE
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
- (2020) Philip N. Newsome et al. NEW ENGLAND JOURNAL OF MEDICINE
- Non-Invasive Assessment of Liver Disease in Patients with NAFLD
- (2019) Laurent Castera et al. GASTROENTEROLOGY
- Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
- (2019) Peter J. Eddowes et al. GASTROENTEROLOGY
- Prediction of nonalcoholic fatty liver disease (NAFLD) activity score (NAS) with multiparametric hepatic magnetic resonance imaging and elastography
- (2019) Ziying Yin et al. EUROPEAN RADIOLOGY
- Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity
- (2019) Philip Newsome et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial
- (2019) Fernando Bril et al. DIABETES CARE
- Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis
- (2019) Srilaxmi Kalavalapalli et al. JOURNAL OF ENDOCRINOLOGY
- The Global Epidemiology of NAFLD and NASH in Patients with type 2 diabetes: A Systematic Review and Meta-analysis
- (2019) Zobair M. Younossi et al. JOURNAL OF HEPATOLOGY
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2019) Mansoor Husain et al. NEW ENGLAND JOURNAL OF MEDICINE
- A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe
- (2019) Jeffrey V. Lazarus et al. JOURNAL OF HEPATOLOGY
- Glucagon-like peptide 1 (GLP-1)
- (2019) T.D. Müller et al. Molecular Metabolism
- Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes
- (2019) Fernando Bril et al. DIABETES CARE
- Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the United States
- (2019) Zobair M. Younossi et al. DIABETES CARE
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2019) Søren L Kristensen et al. Lancet Diabetes & Endocrinology
- Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity
- (2019) Zachary J. Ward et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis
- (2018) Alessandro Mantovani et al. DIABETES CARE
- A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin
- (2018) Ildiko Lingvay et al. DIABETES CARE
- Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme
- (2018) K. Cusi et al. DIABETIC MEDICINE
- Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
- (2018) Patrick M O'Neil et al. LANCET
- Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies
- (2018) Norbert Stefan et al. Lancet Diabetes & Endocrinology
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
- (2017) Naga Chalasani et al. HEPATOLOGY
- Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis
- (2017) Parambir S. Dulai et al. HEPATOLOGY
- Glucagon like peptide-1 receptor agonists for the management of obesity and non-alcoholic fatty liver disease: a novel therapeutic option
- (2017) Gauri Dhir et al. JOURNAL OF INVESTIGATIVE MEDICINE
- 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
- (2017) Carel W le Roux et al. LANCET
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease
- (2017) Wenhuan Feng et al. Journal of Diabetes
- Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis
- (2017) Giovanni Musso et al. JAMA Internal Medicine
- Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus
- (2016) Kenneth Cusi et al. ANNALS OF INTERNAL MEDICINE
- Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial
- (2016) A Blackman et al. INTERNATIONAL JOURNAL OF OBESITY
- Mechanisms of Action of Liraglutide in Patients With Type 2 Diabetes Treated With High-Dose Insulin
- (2016) Anna Vanderheiden et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
- (2016) JOURNAL OF HEPATOLOGY
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis
- (2015) Feng Sun et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study
- (2015) Raymond Kwok et al. GUT
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes
- (2015) Melanie J. Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody
- (2014) Charles Pyke et al. ENDOCRINOLOGY
- Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study
- (2013) T A Wadden et al. INTERNATIONAL JOURNAL OF OBESITY
- GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic MaleApoE−/−Mice
- (2012) Naim Panjwani et al. ENDOCRINOLOGY
- The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone
- (2012) Takamasa Ohki et al. TheScientificWorldJOURNAL
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- (2010) Arun J. Sanyal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis
- (2008) Guruprasad P. Aithal et al. GASTROENTEROLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started